Very high HDL may actually be harmful in men, not protective
For generations, medicine held that high HDL cholesterol was an unambiguous sign of a heart well-defended — a number to pursue without reservation. A large study drawing on over 100,000 participants in the UK Biobank has quietly dismantled that certainty, finding that men with very high HDL levels face nearly double the risk of cardiovascular and all-cause mortality, while women with the same elevated readings show no such danger. The discovery does not invert the value of HDL so much as reveal that the body's relationship with this molecule is shaped by biology, sex, and complexity that a single number on a blood test cannot capture. What was once a reassuring figure has become a reminder that medical certainty is always provisional.
- A cornerstone of cardiovascular medicine — the belief that higher HDL cholesterol always protects the heart — is now under serious scientific pressure.
- Men with HDL above 80 mg/100ml face nearly double the risk of dying from cardiovascular causes compared to men with normal levels, a finding that cuts against decades of clinical guidance.
- Women with identically elevated HDL show no increased mortality risk, exposing a sharp biological divide that neither patients nor many clinicians were prepared for.
- The structural integrity of HDL particles at very high levels may be compromised, carrying both pro- and anti-inflammatory signals in ways science does not yet fully understand.
- Multiple pharmaceutical programs built around raising HDL are now further undermined, as the study questions whether artificially elevated HDL mimics the profile of naturally high HDL at all.
- Clinicians are being urged to abandon HDL as a standalone risk predictor and to situate cholesterol readings within a far broader picture of cardiovascular health.
For decades, a rising HDL number on a blood test felt like good news — the kind of medical certainty patients and doctors could lean on together. A new study published in the American Journal of Cardiology, drawing on data from more than 100,000 UK Biobank participants tracked over nine years, has introduced a significant complication into that story.
Researchers found that men whose HDL cholesterol exceeded 80 mg per 100 milliliters — a level most would consider excellent — faced nearly double the risk of cardiovascular and all-cause mortality compared to men with normal HDL levels. About two percent of men in the biobank fell into this elevated category, and the elevated numbers carried measurable harm rather than protection.
Women told a strikingly different story. Eleven percent of female participants had similarly high HDL, yet showed no increased mortality risk. Genetic analysis of 142 HDL-associated variants confirmed the pattern: the protective effect held for women even after accounting for genetic factors, while the risk in men persisted. The researchers noted that naturally high HDL tends to appear in women with lower body weight and lower triglycerides — a profile that pharmaceutical interventions may not replicate.
One explanation points to the HDL particles themselves. At very high concentrations, these particles may become structurally compromised, carrying both pro- and anti-inflammatory properties that interact with the immune system in poorly understood ways. The relationship between HDL and heart health, it turns out, is not linear — the benefits of moderate elevation appear to plateau and then reverse, at least in men.
The findings arrive as clinical trials have already failed to show that drugs designed to raise HDL reduce cardiovascular events. The study does not argue for low HDL, but it firmly challenges the assumption that more is always better. For clinicians, the message is pointed: a high HDL reading is no longer automatically reassuring, and cholesterol management must now contend with a more complicated reality than the simple numbers once suggested.
For decades, doctors have told patients that high HDL cholesterol—the so-called good cholesterol—is something to chase. The higher, the better. It's been the kind of medical wisdom that feels almost self-evident: a number climbing in the right direction on a blood test. But a new study from the UK Biobank is forcing a reconsideration of that assumption, at least for men, and the findings are unsettling enough to reshape how clinicians think about cholesterol risk.
Researchers publishing in the American Journal of Cardiology examined data from over 100,000 UK Biobank participants, aged 37 to 73, who had no prior history of coronary artery disease. The team tracked these people for an average of nine years, watching for cardiovascular events and deaths. What they found was counterintuitive: men whose HDL cholesterol climbed above 80 mg per 100 milliliters—a level most would consider excellent—faced nearly double the risk of dying from cardiovascular causes or any cause compared to men with normal HDL levels between 40 and 60 mg per 100 milliliters. Two percent of the male population in the biobank fell into this very high category, and their elevated numbers translated into measurable harm.
Women, however, told a different story. Eleven percent of the women in the study had similarly elevated HDL cholesterol, yet they showed no increased mortality risk. This gender divide is the study's most striking finding, suggesting that the relationship between HDL and heart health is not universal but shaped by biological differences between men and women. The researchers used genetic analysis to explore why, examining 142 genetic variants associated with HDL cholesterol. Even accounting for these genetic factors, the protective effect of high HDL in women persisted while the risk in men remained.
The implications are troubling for a field that has invested heavily in pharmaceutical interventions designed to raise HDL levels. If very high HDL is not protective—and may actually be harmful in men—then the entire rationale for these drugs comes into question. The study suggests that HDL cholesterol, long treated as a straightforward marker of cardiovascular health, is far more complicated than the simple "higher is better" narrative suggests. The researchers noted that patients with very high HDL tended to be women with lower body weight and lower triglyceride levels, suggesting that the profile of someone with naturally elevated HDL differs from what pharmaceutical interventions might create.
One possible explanation lies in the structure and function of HDL particles themselves. The researchers found that people with very high HDL levels may have HDL particles that are compromised in their ability to do their job—particles that have altered structure and functionality. These particles carry both pro-inflammatory and anti-inflammatory properties, meaning they influence the immune system in ways that are not yet fully understood. Very high levels might trigger systemic inflammation, though paradoxically, C-reactive protein levels, a marker of inflammation, were lower in the highest HDL group, likely because these individuals had fewer traditional cardiovascular risk factors to begin with.
The study does not suggest that people should aim for low HDL cholesterol. Rather, it challenges the assumption that HDL operates on a simple linear scale where more is always better. The relationship appears to be nonlinear, particularly in men, where the benefits of moderate HDL elevation plateau and then reverse. This finding arrives at a moment when the field is already questioning whether raising HDL through medication actually prevents heart disease—multiple clinical trials have failed to show that drugs designed to boost HDL reduce cardiovascular events.
For clinicians, the message is clear: HDL cholesterol should no longer be used as a standalone predictor of cardiovascular risk. A high number on a blood test is not automatically reassuring, especially for men. The researchers call for further investigation into interventions that might reduce the risk associated with very high HDL in men, and they emphasize that HDL measurements need to be interpreted within a broader context of overall cardiovascular health. The comfortable certainty that guided cholesterol management for years has given way to a more complicated reality.
Notable Quotes
Very high HDL levels are markers of high risk in men alone, and high HDL levels are not deemed a reliable marker of heart protection in current clinical practice— Study authors, American Journal of Cardiology
These findings partially explain the lack of usefulness of pharmaceutical interventions targeted at increasing HDL-C levels— Study authors
The Hearth Conversation Another angle on the story
Why would very high HDL be dangerous? Isn't the whole point of HDL that it clears bad cholesterol from the arteries?
That's the conventional understanding, and it's not wrong for moderate levels. But the study suggests that when HDL gets very high, the particles themselves may become dysfunctional—their structure changes in ways that actually promote inflammation rather than prevent it.
So it's not the cholesterol itself that's the problem, but what happens to the particles when there's too much of it?
Exactly. And the particles have both inflammatory and anti-inflammatory properties. At very high levels, the balance tips. The researchers found these particles are compromised in their ability to do protective work.
Why does this only affect men? What's different about how women's bodies handle very high HDL?
That's the mystery the study couldn't fully answer. Women have physiologic modulators of lipid metabolism that men don't have. Eleven percent of women in the study had very high HDL with no increased mortality risk, while only two percent of men did, and those men faced double the risk.
Could it be that the women with very high HDL are just healthier overall—lower weight, better habits?
The researchers controlled for that. Even accounting for BMI, triglycerides, diabetes, and genetic factors, the gender difference persisted. It's not explained by lifestyle or the usual risk factors.
What does this mean for people taking drugs to raise their HDL?
It raises serious questions. If very high HDL doesn't protect—and may harm—then the entire rationale for these medications collapses. Multiple trials have already shown they don't prevent heart attacks. This study suggests why: you can't just push HDL higher and expect benefit.
So what should someone do if their HDL is naturally very high?
That's the uncomfortable answer the study doesn't fully address. It suggests HDL should be interpreted as part of a broader picture of cardiovascular health, not as a reassuring number on its own. For men especially, very high HDL might warrant closer monitoring rather than celebration.